Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00397293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer After Prior Platinum Containing First Line Chemotherapy
Study identification
- NCT ID
- NCT00397293
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- AT-101 Drug
- topotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Nov 30, 2008
- Completion
- Nov 30, 2008
- Last update posted
- Aug 23, 2010
2006 – 2008
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Hot Springs | Arkansas | — | — |
| Not listed | Loma Linda | California | 92354 | — |
| Not listed | Stamford | Connecticut | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Lake City | Florida | — | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Lebanon | New Hampshire | — | — |
| Not listed | High Point | North Carolina | — | — |
| Not listed | Portland | Oregon | 97213 | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Hilton Head Island | South Carolina | — | — |
| Not listed | Germantown | Tennessee | — | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Burlington | Vermont | 05405 | — |
| Not listed | Huntington | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00397293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2010 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00397293 live on ClinicalTrials.gov.